Chest
-
Lung Cancer ISESSION TYPE: Slide PresentationsPRESENTED ON: Saturday, March 22, 2014 at 02:15 PM - 03:45 PMPURPOSE: To report local control and overall survival following CyberKnife treatment for central NSCLC conventional radiation failures. ⋯ Sean Collins: Consultant fee, speaker bureau, advisory committee, etc.: Consultant Accuray Inc. Brian Collins: Consultant fee, speaker bureau, advisory committee, etc.: Speaker Bureau Accuray Inc. The following authors have nothing to disclose: Ryan Malik, Shaan Kataria, Catherine Jamis, Leonard Chen, Simeng Suy, Cristina Reichner, Eric AndersonNo Product/Research Disclosure Information.
-
Nocturnal hypoxia, the hallmark of OSA, is a potential contributing factor for nonalcoholic fatty liver disease (NAFLD). NAFLD severity and its implication in OSA-related endothelial dysfunction have not been investigated in a large, unselected OSA population, including nonobese subjects. ⋯ In a large, unselected OSA population, the severity of nocturnal hypoxia was independently associated with steatosis. Preexisting obesity exacerbated the effects of nocturnal hypoxemia. NAFLD is a potential mechanism of endothelial dysfunction in OSA.
-
COPD QVA149 PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Current COPD treatment guidelines recommend long-acting β2-agonist/inhaled corticosteroids (LABA/ICS) for severe COPD patients with a history of exacerbations. The 26-week ILLUMINATE study in moderate-to-severe COPD patients showed superiority of QVA149 versus the LABA/ICS salmeterol/fluticasone combination (SFC) in lung function. A novel study design to evaluate the effect of QVA149 versus SFC on COPD exacerbations in more severe patients with a history of exacerbations is presented. ⋯ Jadwiga Wedzicha: Consultant fee, speaker bureau, advisory committee, etc.: JW has received speaking fee and/or for advisory boards from GlaxoSmithKline, AstraZeneca, Novartis, Bayer, Boehringer Ingelheim, Nycomed. Chiesi and Respifor as well as travel reimbursements from Boehringer Ingelheim. JW has received research grants from GlaxoSmithKline, AstraZeneca, Chiesi and Novartis. Nicola Gallagher: Employee: Novartis employee Donald Banerji: Employee: Novartis employee The following authors have nothing to disclose: Jørgen VestboClinical trial results of QVA149, combination of two approved products indacaterol and glycopyrronium, will be presented, QVA is in the late stage phase 3 trials prior to approval.
-
DVT/PE PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Our goal has been to study long-term survival and main causes of mortality in patients with acute pulmonary embolism (APE). ⋯ The following authors have nothing to disclose: Hernando Chávez Roldán, Jacinto Hernández Borge, María del Carmen García García, Pedro Pires Goncalves, María Teresa Gómez Vizcaíno, Amparo Sanz Cabrera, María José Antona Rodríguez, Pilar Cordero Montero, Ana Castañar Jover, Ignacio Rodríguez BlancoNo Product/Research Disclosure Information.
-
Pleural Disease/Pneumothorax PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Pneumothorax continues to be a major cause of morbidity and mortality among the respiratory patients but there is paucity of data regarding aetiology, clinical profile, management and outcome of Spontaneous Pneumothorax (SP) from this part of the world. Therefore, this study was carried out to determine the aetiology, clinical presentation, management and outcomes of Spontaneous pneumothorax in a tertiary care Hospital from eastern India. ⋯ The following authors have nothing to disclose: Aparup Dhua, Sourin Bhuniya, Arunabha Datta Chaudhuri, Sumit Raytapadar, Tapan Das BairagyaNo Product/Research Disclosure Information.